Disease-Modifying Antirheumatic Drug (DMARD) Market Analysis & Forecast: 2026-2033
The global Disease-Modifying Antirheumatic Drug (DMARD) Market is anticipated to grow at a CAGR of 3.5% during 2026–2033, with the market estimated at USD 23.72 Bn in 2026 and expected to reach approximately USD 30.18 Bn by 2033. The market growth is primarily driven by the rising prevalence of rheumatoid arthritis and other autoimmune disorders, increasing adoption of biologic and targeted synthetic DMARDs. According to a 2025 nationwide cohort study published in the journal Rheumatology, tumor necrosis factor inhibitors (TNFi) continued to be the most common first biologic therapy for rheumatoid arthritis patients, accounting for 62.6% of initial biologic or targeted synthetic DMARD prescriptions, this finding highlights the ongoing clinical reliance on advanced DMARD therapies in routine practice.
Based on drug type, the Synthetic DMARDs (sDMARDs) segment is expected to dominate the Disease-Modifying Antirheumatic Drug (DMARD) Market in 2026 with a share of 54.8%. The segment’s growth is fueled by its sustained status as the preferred first-line treatment option, lower acquisition prices, widespread availability across healthcare systems, and strong backing from international treatment standards. Conventional DMARDs like methotrexate are still considered the main form of treatment for rheumatoid arthritis before moving on to other advanced forms of drugs.
According to a 2025 study published in Clinical Characteristics, Medication Use, and Short-Term Outcomes in Rheumatoid Arthritis Patients in the year 2025, it was stated that out of the total RA patients, 98.35% were being administered conventional synthetic DMARDs (csDMARDs).
In October 2025, Beta Drugs Limited announced that it had received approval from the Drug Controller General of India (DCGI) to launch India's first Methotrexate Oral Solution, a patient-friendly formulation indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, psoriasis, and other conditions.
To learn more about this report, Request Free Sample
The oral segment is projected to dominate with a 58.5% share by 2026. The increase is attributable to the widespread use of oral methotrexate, hydroxychloroquine and leflunomide and rising clinician trust in oral targeted synthetic DMARDs. Oral medicines are convenient, decrease the burden of administration and promote patient acceptance for long-term treatment.
Moreover, according to a patient outcomes survey conducted in 2024, roughly 68% of RA patients with rheumatoid arthritis preferred oral medications over injectables based on ease of use and minimal disruption during therapy sessions.
In April 2025, AbbVie announced that the European Commission approved RINVOQ® (upadacitinib), an oral Janus kinase (JAK) inhibitor, for the treatment of adults with giant cell arteritis (GCA).
By indication, the Rheumatoid Arthritis segment is projected to capture the largest share of 67.4% of the DMARD Market by 2026. The growth in this market segment can be attributed to the high prevalence of the disease, its chronicity, the need for lifelong disease modification, and treat-to-target approaches.
According to a 2025 Global Burden of Disease analysis published in Biomarker Research predicts the worldwide number of people with rheumatoid arthritis will grow by about 80% by 2050 versus current numbers, emphasizing the growing patient population needing DMARD therapy.
In December 2025, Adaptive Biotechnologies announced that it had entered into two non-exclusive agreements with Pfizer Inc. to advance research and drug discovery for rheumatoid arthritis.
Based on distribution channel, the hospital pharmacy segment is projected to dominate with a significant share of 52.6% in 2026. The expansion is fuelled by specialist-led prescribing practices, administration demands related to biologic treatments, patient monitoring needs, reimbursement management, and integrated multidisciplinary care delivery.
According to a 2025 Scottish National Prescribing Study on advanced DMARD use, it was found that specialist hospital associated homecare and institutional pharmacy networks supplied around 78% of biologic DMARD prescriptions, demonstrating the importance of hospital-based distribution systems.
The Disease-Modifying Antirheumatic Drug (DMARD) Market is being driven by greater attention to early diagnosis and treat-to-target methods. Rheumatology guidelines increasingly suggest early beginning and optimization of DMARD therapy to achieve remission or low disease activity before permanent joint injury. This change has contributed to an increased use of traditional, biologic and targeted synthetic DMARDs throughout healthcare systems around the world.
According to the Arthritis Foundation reports that remission rates can be higher than 60% when rheumatoid arthritis is treated early with DMARDs and biologic treatments, but delayed treatment start is linked to significantly lower remission rates varying from 10% to 33%. These results highlight the clinical and economic implications of early diagnosis and aggressive intervention approaches.
In March 2026, EULAR issued its 2025 version of recommendations regarding the use of synthetic and biological DMARDs for treating rheumatoid arthritis and confirmed the need for prescribing DMARD treatment at the time of RA diagnosis and subsequent modifications of the treatment on a 'treat to target' principle until achieving sustained remission or low disease activity state.
Continuous innovation with biologic DMARDs, biosimilar drugs, and target-specific synthetic drugs are bringing significant changes to the area of DMARD treatments. The emergence of new drugs based on innovative methods of treatment, greater efficacy, and broader indications is increasing treatment options for patients who fail to achieve adequate levels of disease control by traditional means.
In September 2024, UCB announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation and active ankylosing spondylitis (AS).
|
Current Event |
Description and its Impact |
|
Expansion of Biosimilar Adoption Improves Access to Advanced DMARD Therapies (2025–2026) |
|
|
Personalized Medicine and Precision Therapeutics Gain Momentum in Autoimmune Care (2025–2026) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
North America will have a 41.3% share of the Disease-Modifying Antirheumatic Drug (DMARD) Market in 2026. The expansion of the market in the region is attributed to favorable reimbursement policies, increasing usage of biologic and targeted medicines, upgraded healthcare infrastructure and increased access to rheumatology specialists. High knowledge of early diagnosis and treat-to-target techniques further helps the uptake of DMARD therapy in the region.
According to the 2025 American College of Rheumatology (ACR) Rheumatology Workforce Study, the United States had 5,667 clinically active adult rheumatologists and 379 advanced practice providers, highlighting a growing specialist workforce that supports improved access to disease-modifying therapies and comprehensive rheumatology care nationwide.
In May 2025, Teva Pharmaceuticals and Alvotech announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI™ (ustekinumab-aekn) as an interchangeable biosimilar to Stelara® (ustekinumab) in all presentations that match the reference product.
The Asia Pacific region is projected to experience the fastest growth in the Disease-Modifying Antirheumatic Drug (DMARD) Market during the forecast period. Growth in the region is attributed to increased access to healthcare, increasing health insurance coverage, rising knowledge of autoimmune disorders, increasing rates of diagnosis, and increasing availability of affordable biosimilars in emerging economies such as China and India.
Furthermore, the 2025 Asia Pacific League of Associations for Rheumatology (APLAR) projects also focused on enhancing early arthritis diagnosis and expanding rheumatology capacity throughout developing Asian countries, hence promoting better access to disease-modifying medication.
In May 2024, Eisai Co., Ltd. and Nippon Medac launched Metoject Subcutaneous Injection Pen in Japan, enabling self-administration of methotrexate for rheumatoid arthritis patients.
The U.S. DMARD market is registering robust growth on the back of high disease burden, improved healthcare infrastructure, quick uptake of biologics and increasing biosimilar penetration. The country’s focus on early diagnosis and treat-to-target approaches continue to underpin long-term DMARD use in rheumatoid arthritis and other autoimmune diseases.
Moreover, the U.S. FDA’s approval of the SetPoint Medical System in July 2025 represented the first neuroimmune modulation therapy for rheumatoid arthritis patients with an inadequate response to DMARDs, a move toward innovative non-pharmacologic treatment options in the U.S. autoimmune market.
China’s DMARD market is expanding rapidly, fueled by the increasing incidence of rheumatoid arthritis, better access to healthcare, robust local pharmaceutical manufacturing, and government programs that encourage biosimilars and innovation drugs.
According to a 2025 Global Burden of Disease published in Biomarker Research, East Asia (including China) accounted for a large share of the worldwide burden of rheumatoid arthritis in 2025, with the number of patients still rising due to aging populations and improved detection rates. This rising illness burden is a major driver for growing demand for DMARDs across the country.
In September 2024, China’s NMPA officially approved Xeligekimab Injection (Jinlixi), developed by Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd., for the treatment of adult patients with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy.
Some of the major key players in Disease-Modifying Antirheumatic Drug (DMARD) Market are Sanofi., Pfizer, F. Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB, Bristol-Myers Squibb Company, UCB S.A., Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 23.72 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.5% | 2033 Value Projection: | USD 30.18 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Sanofi., Pfizer, F. Hoffman-La Roche AG, Johnson & Johnson, AbbVie Inc., Eli Lilly & Company, Amgen Inc., Swedish Orphan Biovitrum AB, Bristol-Myers Squibb Company, UCB S.A., Gilead Sciences, Inc., and Cumberland Pharmaceuticals Inc |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
